Germany Joins Probe Of China Heparin Sources
This article was originally published in PharmAsia News
Executive Summary
German authorities are joining in the search for answers to the contamination in China of active ingredients in the blood-thinner heparin. The drug produced by Rotexmedica has been linked to about 80 allergic reactions in German patients, leading to a national recall. German authorities identified Changzhou Quianhong Bio Pharma and Yantai Dongcheng Biochemicals as the sources of heparin API and asked heparin producers to check to see if their API came from China. Although the U.S. FDA said its investigation of the Baxter source found concentrations as high as 20 percent of a substance that may be counterfeit, it has not established whether the same substance was responsible for allergic reactions. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.